AB801 is a potent and selective AXL inhibitor that demonstrates significant anti-tumor activity in combination with standard of care therapeutics. (October 2022) - Paprcka, S.; Sridhar, S.; Goshayeshi, A.; Park, E.; Liu, S.; Flores, R.; Rocha, L.; Miles, D.; Lamani, M.; Cho, S.; Wang, N.; Guan, Y.; et al.